{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:49:19Z","timestamp":1794019759535,"version":"4.8.0"},"reference-count":202,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["CRG\/2021\/002419"],"award-info":[{"award-number":["CRG\/2021\/002419"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.heliyon.2022.e10450","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T12:16:35Z","timestamp":1661602595000},"page":"e10450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8497-0765","authenticated-orcid":false,"given":"Mitesh","family":"Dwivedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Helen","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasheedunnisa","family":"Begum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2022.e10450_bib1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.autrev.2016.01.002","article-title":"Induction of regulatory T cells: a role for probiotics and prebiotics to suppress autoimmunity","volume":"15","author":"Dwivedi","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.heliyon.2022.e10450_bib2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nm.4086","article-title":"Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers","volume":"22","author":"Saito","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2022.e10450_bib3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/intimm\/dxw025","article-title":"Roles of regulatory T cells in cancer immunity","volume":"28","author":"Takeuchi","year":"2016","journal-title":"Int. Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1146\/annurev-cancerbio-030419-033428","article-title":"Regulatory T cells in cancer","volume":"4","author":"Plitas","year":"2020","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib5","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.heliyon.2022.e10450_bib6","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.4049\/jimmunol.136.5.1888","article-title":"Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response","volume":"136","author":"Mukherji","year":"1986","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07357908809080657","article-title":"Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide","volume":"6","author":"Berd","year":"1988","journal-title":"Cancer Invest."},{"key":"10.1016\/j.heliyon.2022.e10450_bib8","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib10","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.4049\/jimmunol.169.5.2756","article-title":"Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma","volume":"169","author":"Liyanage","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib11","first-page":"4766","article-title":"Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer","volume":"61","author":"Woo","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ygyno.2003.09.020","article-title":"Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients","volume":"92","author":"Fattorossi","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib13","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2022.e10450_bib14","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1158\/1078-0432.CCR-05-1244","article-title":"The expression of the regulatory T cell\u2013specific forkhead Box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer","volume":"11","author":"Wolf","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib15","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/cncr.11618","article-title":"CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression","volume":"98","author":"Sasada","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.heliyon.2022.e10450_bib16","first-page":"4404","article-title":"Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers","volume":"9","author":"Ichihara","year":"2003","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib17","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-04-3232","article-title":"Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma","volume":"65","author":"Ormandy","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib18","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/hep.20644","article-title":"Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells","volume":"41","author":"Unitt","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2022.e10450_bib19","first-page":"2551","article-title":"Association of increased levels of heavy-chain ferritin with increased CD4+ CD25+ regulatory T-cell levels in patients with melanoma","volume":"9","author":"Gray","year":"2003","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib20","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.4049\/jimmunol.173.2.1444","article-title":"Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells","volume":"173","author":"Viguier","year":"2004","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib21","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood-2005-02-0642","article-title":"Reduced frequencies and suppressive\u00a0function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine","volume":"106","author":"Beyer","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2022.e10450_bib22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.2004.04999.x","article-title":"Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia\/lymphoma cells","volume":"126","author":"Karube","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib23","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1182\/blood-2004-06-2181","article-title":"Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells","volume":"105","author":"Berger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2022.e10450_bib24","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/sj.bjc.6602407","article-title":"Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer","volume":"92","author":"Schaefer","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.heliyon.2022.e10450_bib25","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/sj.leu.2404913","article-title":"FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival","volume":"21","author":"Gjerdrum","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2022.e10450_bib26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00262-005-0697-y","article-title":"Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck","volume":"55","author":"Sakakura","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.heliyon.2022.e10450_bib27","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1002\/cncr.22282","article-title":"Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients","volume":"107","author":"Petersen","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.heliyon.2022.e10450_bib28","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1158\/1078-0432.CCR-07-4554","article-title":"HLA Class I, MICA and CD8+\/regulatory T-cell ratio: which parameter determines survival of cervical cancer patients","volume":"14","author":"Jordanova","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib29","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1200\/JCO.2006.05.9584","article-title":"Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse","volume":"24","author":"Bates","year":"2006","journal-title":"J.\u00a0Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib30","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-06-0369","article-title":"Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions","volume":"12","author":"Hiraoka","year":"2006","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib31","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1053\/j.gastro.2007.03.102","article-title":"Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients","volume":"132","author":"Fu","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.heliyon.2022.e10450_bib32","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.4049\/jimmunol.168.9.4272","article-title":"Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation","volume":"168","author":"Woo","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib33","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood-2003-07-2594","article-title":"Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma","volume":"103","author":"Marshall","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2022.e10450_bib34","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1007\/s00262-005-0092-8","article-title":"CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers","volume":"55","author":"Kono","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.heliyon.2022.e10450_bib35","first-page":"167","article-title":"Regulatory T cells and myeloid-derived suppressor cells in patients with peptic ulcer and gastric cancer","volume":"13","author":"Mesali","year":"2016","journal-title":"Iran J. Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib36","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3748\/wjg.v18.i1.34","article-title":"Increased numbers of Foxp3-positive regulatory T cells in gastritis, peptic ulcer and gastric adenocarcinoma","volume":"18","author":"Cheng","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jss.2004.10.004","article-title":"Distribution of CD4 (+) CD25 high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer","volume":"125","author":"Kawaida","year":"2005","journal-title":"J.\u00a0Surg. Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib38","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1158\/1078-0432.CCR-04-1869","article-title":"Outcome in Hodgkin\u2019s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells","volume":"11","author":"Alvaro","year":"2005","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib39","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1200\/JCO.2006.09.4565","article-title":"Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection","volume":"25","author":"Gao","year":"2007","journal-title":"J.\u00a0Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib40","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1158\/1078-0432.CCR-06-2363","article-title":"FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis","volume":"13","author":"Kobayashi","year":"2007","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib41","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.3892\/ol.2016.5252","article-title":"Prognostic impact of the tumor-infiltrating regulatory T-cell (Foxp3 +)\/activated cytotoxic T lymphocyte (granzyme B +) ratio on resected left-sided pancreatic cancer","volume":"12","author":"Hwang","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.heliyon.2022.e10450_bib42","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00007890-197409000-00007","article-title":"Immunological enhancement of tumor growth by syngeneic thymus-derived lymphocytes","volume":"18","author":"Umiel","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.heliyon.2022.e10450_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0008-8749(75)90048-9","article-title":"Elimination of suppressor T-cells in mice undergoing a graft-versus-host reaction expressed by increased response to polyvinylpyrrolidone","volume":"18","author":"Rotter","year":"1975","journal-title":"Cell Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib44","first-page":"1805","article-title":"Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens","volume":"46","author":"Bear","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib45","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1084\/jem.159.5.1295","article-title":"Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells","volume":"159","author":"North","year":"1984","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.heliyon.2022.e10450_bib46","first-page":"87","article-title":"Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden","volume":"65","author":"Awwad","year":"1988","journal-title":"Immunology"},{"key":"10.1016\/j.heliyon.2022.e10450_bib47","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1084\/jem.20111497","article-title":"Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth","volume":"209","author":"Hansen","year":"2012","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.heliyon.2022.e10450_bib48","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10169","article-title":"Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells","volume":"475","author":"Facciabene","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2022.e10450_bib49","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0092-8674(00)81402-6","article-title":"Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor","volume":"92","author":"Soker","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2022.e10450_bib50","first-page":"129","article-title":"Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells","volume":"12","author":"Price","year":"2001","journal-title":"Cell Growth Differ. Mol. Biol. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib51","doi-asserted-by":"crossref","first-page":"15179","DOI":"10.1038\/srep15179","article-title":"Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis","volume":"5","author":"Shang","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2022.e10450_bib52","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.immuni.2016.10.032","article-title":"Regulatory T cells exhibit distinct features in human breast cancer","volume":"45","author":"Plitas","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2022.e10450_bib53","doi-asserted-by":"crossref","first-page":"108469","DOI":"10.1016\/j.intimp.2021.108469","article-title":"Immunotherapy of cancer by targeting regulatory T cells","volume":"104","author":"Chen","year":"2022","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.heliyon.2022.e10450_bib54","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.immuni.2016.10.021","article-title":"Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells","volume":"45","author":"De Simone","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2022.e10450_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aak9537","article-title":"Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin","volume":"9","author":"Zheng","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2022.e10450_bib56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1074-7613(03)00359-5","article-title":"Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy","volume":"20","author":"Wang","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2022.e10450_bib57","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2005-02-0607","article-title":"CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients","volume":"106","author":"Nishikawa","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2022.e10450_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of cancer: current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib59","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1073\/pnas.97.9.4760","article-title":"Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses","volume":"97","author":"J\u00e4ger","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.heliyon.2022.e10450_bib60","article-title":"Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies","volume":"9","author":"Nishikawa","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.heliyon.2022.e10450_bib61","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nrc3557","article-title":"Serine, glycine and one-carbon units: cancer metabolism in full circle","volume":"13","author":"Locasale","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.heliyon.2022.e10450_bib62","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41590-019-0589-5","article-title":"CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors","volume":"21","author":"Wang","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib63","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41586-021-03235-6","article-title":"Lipid signalling enforces functional specialization of T reg cells in tumours","volume":"591","author":"Lim","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2022.e10450_bib64","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cmet.2016.12.018","article-title":"Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments","volume":"25","author":"Angelin","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.heliyon.2022.e10450_bib65","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.immuni.2020.06.016","article-title":"An oncogenic alteration creates a microenvironment that promotes tumor progression by conferring a metabolic advantage to regulatory T cells","volume":"53","author":"Kumagai","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2022.e10450_bib66","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2015.09.001","article-title":"Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity","volume":"163","author":"Serrels","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2022.e10450_bib67","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1084\/jem.20050463","article-title":"Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation","volume":"202","author":"Ghiringhelli","year":"2005","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.heliyon.2022.e10450_bib68","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/1348-0421.12168","article-title":"Effect of HIF1\u03b1 on Foxp3 expression in CD4+ CD25- T lymphocytes","volume":"58","author":"Wu","year":"2014","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib69","article-title":"Intratumor hypoxia promotes immune tolerance by inducing regulatory T cells via TGF-\u03b21 in gastric cancer","volume":"8","author":"Deng","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2022.e10450_bib70","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1182\/blood-2006-02-004747","article-title":"IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo","volume":"108","author":"Zorn","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2022.e10450_bib71","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ijc.30077","article-title":"PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma","volume":"139","author":"Ruf","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.heliyon.2022.e10450_bib72","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.immuni.2012.09.010","article-title":"T\u00a0cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development","volume":"37","author":"Ohkura","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2022.e10450_bib73","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1126\/science.1227049","article-title":"Regulatory T cells increase the avidity of primary CD8+ T cell responses and promote memory","volume":"338","author":"Pace","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2022.e10450_bib74","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1126\/science.aaa1292","article-title":"Detection of self-reactive CD8+ T cells with an anergic phenotype in healthy individuals","volume":"346","author":"Maeda","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2022.e10450_bib75","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.heliyon.2022.e10450_bib76","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2022.e10450_bib77","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1084\/jem.188.2.287","article-title":"CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production","volume":"188","author":"Thornton","year":"1998","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.heliyon.2022.e10450_bib78","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2022.e10450_bib79","doi-asserted-by":"crossref","first-page":"9253","DOI":"10.1073\/pnas.0503852102","article-title":"Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts","volume":"102","author":"Nishikawa","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.heliyon.2022.e10450_bib80","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/01.cji.0000155049.26787.45","article-title":"CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2","volume":"28","author":"Antony","year":"2005","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.heliyon.2022.e10450_bib81","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib82","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2023739118","article-title":"Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells","volume":"118","author":"Tekguc","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.heliyon.2022.e10450_bib83","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/1521-4141(200006)30:6<1538::AID-IMMU1538>3.0.CO;2-X","article-title":"CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells","volume":"30","author":"Cederbom","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib84","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2022.e10450_bib85","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2022.e10450_bib86","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.4049\/jimmunol.172.7.4100","article-title":"Ligation of B7-1\/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells","volume":"172","author":"Munn","year":"2004","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib87","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1158\/1078-0432.CCR-11-1331","article-title":"Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives","volume":"17","author":"Godin-Ethier","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib88","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/blood-2006-07-036863","article-title":"Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells","volume":"109","author":"Curti","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2022.e10450_bib89","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.4049\/jimmunol.0903670","article-title":"An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells","volume":"185","author":"Mezrich","year":"2010","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib90","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2022.e10450_bib91","doi-asserted-by":"crossref","first-page":"896","DOI":"10.4049\/jimmunol.177.2.896","article-title":"Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells","volume":"177","author":"Jarnicki","year":"2006","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib92","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature06306","article-title":"The inhibitory cytokine IL-35 contributes to regulatory T-cell function","volume":"450","author":"Collison","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2022.e10450_bib93","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.4049\/jimmunol.159.10.4772","article-title":"Induction of tolerance by IL-10-treated dendritic cells","volume":"159","author":"Steinbrink","year":"1997","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib94","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.immuni.2016.01.013","article-title":"Interleukin-35 limits anti-tumor immunity","volume":"44","author":"Turnis","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2022.e10450_bib95","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1172\/JCI200422325","article-title":"Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses","volume":"114","author":"Lim","year":"2004","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.heliyon.2022.e10450_bib96","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1074-7613(02)00298-4","article-title":"The impact of T helper and T regulatory cells on the regulation of anti-double-stranded DNA B cells","volume":"16","author":"Seo","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2022.e10450_bib97","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.4049\/jimmunol.171.9.4604","article-title":"CD4+CD25+ T cells lyse antigen-presenting B cells by Fas-Fas ligand interaction in an epitope-specific manner","volume":"171","author":"Janssens","year":"2003","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib98","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.4049\/jimmunol.177.9.6540","article-title":"Human CD4+CD25+ regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas\/Fas ligand-dependent mechanism","volume":"177","author":"Venet","year":"2006","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib99","doi-asserted-by":"crossref","first-page":"19446","DOI":"10.1073\/pnas.0706832104","article-title":"CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes\/macrophages","volume":"104","author":"Tiemessen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.heliyon.2022.e10450_bib100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00262-006-0160-8","article-title":"Tumor-derived CD4+CD25+ regulatory T cell suppression of dendritic cell function involves TGF-\u03b2 and IL-10","volume":"56","author":"Larmonier","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.heliyon.2022.e10450_bib101","doi-asserted-by":"crossref","first-page":"394","DOI":"10.4049\/jimmunol.170.1.394","article-title":"CD4+CD25+ regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, Leishmania major infection, and colitis in mice","volume":"170","author":"Xu","year":"2003","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib102","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.4049\/jimmunol.1600737","article-title":"Ex-Th17 (nonclassical Th1) cells are functionally distinct from classical Th1 and Th17 cells and are not constrained by regulatory T cells","volume":"198","author":"Basdeo","year":"2017","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib103","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/eji.200324181","article-title":"CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative","volume":"34","author":"Ghiringhelli","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib104","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1084\/jem.20062512","article-title":"Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression","volume":"204","author":"Deaglio","year":"2007","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.heliyon.2022.e10450_bib105","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.4049\/jimmunol.0801279","article-title":"The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells","volume":"182","author":"Wilson","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib106","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00066-016-0948-1","article-title":"Adenosine can thwart antitumor immune responses elicited by radiotherapy : therapeutic strategies alleviating protumor ADO activities","volume":"192","author":"Vaupel","year":"2016","journal-title":"Strahlenther. Onkol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib107","doi-asserted-by":"crossref","first-page":"7946","DOI":"10.1093\/nar\/gkr444","article-title":"Next-generation insights into regulatory T cells: expression profiling and FoxP3 occupancy in Human","volume":"39","author":"Birzele","year":"2011","journal-title":"Nucl. Acid Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib108","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/imr.12174","article-title":"Genetic and epigenetic basis of Treg cell development and function: from a FoxP3-centered view to an epigenome-defined view of natural Treg cells","volume":"259","author":"Morikawa","year":"2014","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.heliyon.2022.e10450_bib109","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1111\/febs.13656","article-title":"Targeting regulatory T cells in tumors","volume":"283","author":"Liu","year":"2016","journal-title":"FEBS J."},{"key":"10.1016\/j.heliyon.2022.e10450_bib110","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1084\/jem.20041684","article-title":"Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors","volume":"201","author":"Yu","year":"2005","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.heliyon.2022.e10450_bib111","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.clim.2004.04.003","article-title":"CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction","volume":"112","author":"Trzonkowski","year":"2004","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib112","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0002-9440(10)63863-1","article-title":"CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice","volume":"162","author":"Erdman","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib113","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1084\/jem.20011347","article-title":"Regulatory CD4+CD25+ T cells restrict memory CD8+ T cell responses","volume":"196","author":"Kursar","year":"2002","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.heliyon.2022.e10450_bib114","first-page":"4516","article-title":"Human CD4+ CD25+ regulatory T cells suppress NKT cell functions","volume":"63","author":"Azuma","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib115","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.immuni.2007.08.014","article-title":"Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance","volume":"27","author":"Cao","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2022.e10450_bib116","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.immuni.2009.04.010","article-title":"Mechanisms of foxp3+ T regulatory cell-mediated suppression","volume":"30","author":"Shevach","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2022.e10450_bib117","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2019.05.003","article-title":"Treg-mediated acquired resistance to immune checkpoint inhibitors","volume":"457","author":"Saleh","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.heliyon.2022.e10450_bib118","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Ann. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib119","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/imcb.1003","article-title":"Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells","volume":"96","author":"Nair","year":"2018","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib120","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib121","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","article-title":"Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments","volume":"40","author":"Kumagai","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.heliyon.2022.e10450_bib122","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.heliyon.2022.e10450_bib123","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.4049\/jimmunol.1202382","article-title":"Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease","volume":"190","author":"Wong","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib124","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.semcancer.2017.10.001","article-title":"Emerging targets in cancer immunotherapy","volume":"52","author":"Burugu","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib125","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.4049\/jimmunol.0903879","article-title":"LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites","volume":"184","author":"Camisaschi","year":"2010","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib126","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1158\/2326-6066.CIR-14-0150","article-title":"Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells","volume":"3","author":"Kouo","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib127","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jff.2015.08.016","article-title":"Selecting probiotics with the abilities of enhancing GLP-1 to mitigate the progression of type 1 diabetes in vitro and in vivo","volume":"18","author":"Wei","year":"2015","journal-title":"J.\u00a0Funct. Foods"},{"key":"10.1016\/j.heliyon.2022.e10450_bib128","doi-asserted-by":"crossref","first-page":"e1239005","DOI":"10.1080\/2162402X.2016.1239005","article-title":"LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma","volume":"5","author":"Deng","year":"2016","journal-title":"Oncoimmunology"},{"issue":"Suppl 2","key":"10.1016\/j.heliyon.2022.e10450_bib129","doi-asserted-by":"crossref","first-page":"i96","DOI":"10.1136\/annrheumdis-2011-200588","article-title":"Roles of LAG3 and EGR2 in regulatory T cells","volume":"71","author":"Okamura","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.heliyon.2022.e10450_bib130","article-title":"Tim-3 expression defines regulatory T cells in human tumors","volume":"8","author":"Yan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2022.e10450_bib131","doi-asserted-by":"crossref","DOI":"10.4161\/onci.23849","article-title":"TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer","volume":"2","author":"Sakuishi","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.heliyon.2022.e10450_bib132","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1158\/1078-0432.CCR-18-1038","article-title":"Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation and regulatory T-cell infiltration","volume":"24","author":"Oweida","year":"2018","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib133","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib134","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1172\/JCI81187","article-title":"TIGIT predominantly regulates the\u00a0immune response via regulatory T cells","volume":"125","author":"Kurtulus","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.heliyon.2022.e10450_bib135","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/intimm\/dxp072","article-title":"PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells","volume":"21","author":"Wang","year":"2009","journal-title":"Int. Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib136","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00262-017-1968-0","article-title":"Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma","volume":"66","author":"Wu","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.heliyon.2022.e10450_bib137","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0065-2776(06)90008-X","article-title":"Checkpoint blockade in cancer immunotherapy","volume":"90","author":"Korman","year":"2006","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib138","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2016.11.007","article-title":"Resistance to PD1\/PDL1 checkpoint inhibition","volume":"52","author":"O\u2019Donnell","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.heliyon.2022.e10450_bib139","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/ITT.S141577","article-title":"Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events","volume":"6","author":"Davies","year":"2017","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.heliyon.2022.e10450_bib140","article-title":"Preclinical development of ipilimumab and nivolumab combination immunotherapy: mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicology","volume":"11","author":"Selby","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2022.e10450_bib141","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1158\/1078-0432.CCR-15-2839","article-title":"Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma","volume":"22","author":"Choueiri","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib142","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/intimm\/dxs098","article-title":"PD-1 is a novel regulator of human B-cell activation","volume":"25","author":"Thibult","year":"2013","journal-title":"Int. Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib143","doi-asserted-by":"crossref","DOI":"10.1038\/srep35651","article-title":"PD-L1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer","volume":"6","author":"Guan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2022.e10450_bib144","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2015.11","article-title":"Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells","volume":"29","author":"Ray","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2022.e10450_bib145","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.it.2014.05.002","article-title":"Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies","volume":"35","author":"Furness","year":"2014","journal-title":"Trends Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib146","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.heliyon.2022.e10450_bib147","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","article-title":"Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells","volume":"1","author":"Selby","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib148","article-title":"Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial","volume":"4","author":"Luke","year":"2016","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.heliyon.2022.e10450_bib149","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/s43018-020-00133-0","article-title":"CD25-T reg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity","volume":"1","author":"Solomon","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.heliyon.2022.e10450_bib150","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","article-title":"ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies","volume":"15","author":"Flynn","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.heliyon.2022.e10450_bib151","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.4049\/jimmunol.173.8.5008","article-title":"Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells","volume":"173","author":"Stephens","year":"2004","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib152","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1084\/jem.20050940","article-title":"Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells","volume":"202","author":"Ko","year":"2005","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.heliyon.2022.e10450_bib153","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1084\/jem.20130573","article-title":"Activating Fc \u03b3 receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies","volume":"210","author":"Bulliard","year":"2013","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.heliyon.2022.e10450_bib154","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1158\/0008-5472.CAN-16-1439","article-title":"Characterization of MK-4166, a clinical agonistic antibody that targets human GITR and inhibits the generation and suppressive effects of T regulatory cells","volume":"77","author":"Sukumar","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib155","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41467-021-21383-1","article-title":"Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells","volume":"12","author":"Duhen","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2022.e10450_bib156","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.immuni.2017.03.013","article-title":"Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors","volume":"46","author":"Arce Vargas","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2022.e10450_bib157","article-title":"TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM","volume":"7","author":"Hung","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.heliyon.2022.e10450_bib158","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/ajt.14661","article-title":"Immunosuppressive effect of the gut microbiome altered by high-dose tacrolimus in mice","volume":"18","author":"Zhang","year":"2018","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"10.1016\/j.heliyon.2022.e10450_bib159","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/0008-5472.CAN-13-1506","article-title":"VISTA regulates the development of protective antitumor immunity","volume":"74","author":"Le Mercier","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib160","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.oraloncology.2016.04.005","article-title":"Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma","volume":"57","author":"Kondo","year":"2016","journal-title":"Oral Oncol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib161","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.1420370112","article-title":"Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses","volume":"112","author":"Liu","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.heliyon.2022.e10450_bib162","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2022.e10450_bib163","doi-asserted-by":"crossref","first-page":"17945","DOI":"10.1073\/pnas.1316796110","article-title":"Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans","volume":"110","author":"Sugiyama","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.heliyon.2022.e10450_bib164","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.1158\/0008-5472.CAN-11-0573","article-title":"Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells","volume":"71","author":"Faget","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib165","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1078-0432.CCR-14-0830","article-title":"Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive\/refractory mycosis fungoides and S\u00e9zary syndrome","volume":"21","author":"Ni","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib166","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1158\/1078-0432.CCR-19-1090","article-title":"A\u00a0phase I study of the anti-CC chemokine receptor 4 antibody, mogamulizumab, in combination with nivolumab in patients with advanced or metastatic solid tumors","volume":"25","author":"Doi","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib167","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J.\u00a0Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib168","article-title":"Therapeutic depletion of CCR8 + tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy","volume":"9","author":"Van Damme","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.heliyon.2022.e10450_bib169","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1158\/0008-5472.CAN-20-3585","article-title":"Fc-optimized anti-CCR8 antibody depletes regulatory T cells in human tumor models","volume":"81","author":"Campbell","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib170","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.immuni.2007.04.017","article-title":"Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor","volume":"27","author":"Yamaguchi","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2022.e10450_bib171","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/21645515.2018.1545625","article-title":"Anti-regulatory T cell vaccines in immunotherapy: focusing on FoxP3 as target","volume":"15","author":"Mousavi-Niri","year":"2019","journal-title":"Hum. Vacc. Immunother."},{"key":"10.1016\/j.heliyon.2022.e10450_bib172","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1158\/0008-5472.CAN-06-2903","article-title":"Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity","volume":"67","author":"Nair","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib173","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.1158\/0008-5472.CAN-10-1736","article-title":"Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma","volume":"70","author":"Klages","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib174","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2147\/OTT.S90476","article-title":"Silencing of Foxp3 delays the growth of murine melanomas and modifies the tumor immunosuppressive environment","volume":"9","author":"Franco-Molina","year":"2016","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.heliyon.2022.e10450_bib175","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/CJI.0000000000000133","article-title":"Improved anti-treg vaccination targeting Foxp3 efficiently decreases regulatory T cells in mice","volume":"39","author":"Mousavi Niri","year":"2016","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.heliyon.2022.e10450_bib176","doi-asserted-by":"crossref","first-page":"10731","DOI":"10.2147\/CMAR.S228887","article-title":"T-regulatory cells in tumor progression and therapy","volume":"11","author":"Verma","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib177","first-page":"141","article-title":"Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide","volume":"16","author":"Motoyoshi","year":"2006","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.heliyon.2022.e10450_bib178","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.heliyon.2022.e10450_bib179","first-page":"502","article-title":"Immuno-modulation linked to the depletion of T regulatory cells contributes to the radiosensitization of tumors by the glycolytic inhibitor 2-Deoxy-DGlucose","volume":"8","author":"A F","year":"2012","journal-title":"J.\u00a0Cancer Res. Ther."},{"key":"10.1016\/j.heliyon.2022.e10450_bib180","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2249.2007.03521.x","article-title":"Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes","volume":"150","author":"Audia","year":"2007","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib181","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/sj.bjc.6605040","article-title":"T-regulatory cell modulation: the future of cancer immunotherapy?","volume":"100","author":"Nizar","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.heliyon.2022.e10450_bib182","doi-asserted-by":"crossref","first-page":"8950","DOI":"10.1200\/JCO.2005.12.147","article-title":"Chemo-immunotherapy of metastatic\u00a0colorectal carcinoma with gemcitabine plus FOLFOX 4 followed\u00a0by\u00a0subcutaneous granulocyte macrophage colony-stimulating factor\u00a0and\u00a0interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer","volume":"23","author":"Correale","year":"2005","journal-title":"J.\u00a0Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib183","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2022.e10450_bib184","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2005.08.032","article-title":"Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte","volume":"123","author":"Gardai","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2022.e10450_bib185","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2217\/fon.09.44","article-title":"Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy","volume":"5","author":"Dwarakanath","year":"2009","journal-title":"Future Oncol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib186","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/ni.3269","article-title":"Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants","volume":"16","author":"De Rosa","year":"2015","journal-title":"Nat. Immunol."},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2022.e10450_bib187","first-page":"S32","article-title":"Protection of normal cells and tissues during radio- and chemosensitization of tumors by 2-deoxy-D-glucose","volume":"5","author":"Farooque","year":"2009","journal-title":"J.\u00a0Cancer Res. Ther."},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2022.e10450_bib188","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.4103\/0973-1482.55137","article-title":"Cytotoxicity, radiosensitization, and chemosensitization of tumor cells by 2-deoxy-D-glucose in vitro","volume":"5","author":"Dwarakanath","year":"2009","journal-title":"J.\u00a0Cancer Res. Ther."},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2022.e10450_bib189","first-page":"S16","article-title":"Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors","volume":"5","author":"Gupta","year":"2009","journal-title":"J.\u00a0Cancer Res. Ther."},{"key":"10.1016\/j.heliyon.2022.e10450_bib190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0360-3016(96)85017-6","article-title":"Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I\/II clinical trials on human cerebral gliomas","volume":"35","author":"Mohanti","year":"1996","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.heliyon.2022.e10450_bib191","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00066-005-1320-z","article-title":"Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme","volume":"181","author":"Singh","year":"2005","journal-title":"Strahlenther. Onkol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib192","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-17750-z","article-title":"Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine","volume":"11","author":"Campesato","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2022.e10450_bib193","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1582-4934.2006.tb00406.x","article-title":"Prospects for exosomes in immunotherapy of cancer","volume":"10","author":"Mignot","year":"2006","journal-title":"J.\u00a0Cell. Mol. Med."},{"key":"10.1016\/j.heliyon.2022.e10450_bib194","first-page":"3747","article-title":"Surface-bound TGF-beta1 on effusion-derived exosomes participates in maintenance of number and suppressive function of regulatory T-cells in malignant effusions","volume":"30","author":"Wada","year":"2010","journal-title":"Anticancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib195","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jhep.2017.05.019","article-title":"Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models","volume":"67","author":"Lu","year":"2017","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib196","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.4049\/jimmunol.179.5.2731","article-title":"Novel exosome-targeted CD4+ T cell vaccine counteracting CD4+ 25+ regulatory T cell-mediated immune suppression and stimulating efficient central memory CD8+ CTL responses","volume":"179","author":"Hao","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib197","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/cmi.2012.37","article-title":"A\u00a0novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling","volume":"10","author":"Xie","year":"2013","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.heliyon.2022.e10450_bib198","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1016\/j.febslet.2011.10.026","article-title":"Thymus, innate immunity and autoimmune arthritis: interplay of gene and environment","volume":"585","author":"Sakaguchi","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.heliyon.2022.e10450_bib199","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature13444","article-title":"Inactivation of PI(3)K p110\u03b4 breaks regulatory T-cell-mediated immune tolerance to cancer","volume":"510","author":"Ali","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2022.e10450_bib200","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1158\/0008-5472.CAN-16-1839","article-title":"Differential PI3K\u03b4 signaling in CD4(+) T-cell subsets enables selective targeting of T regulatory cells to enhance cancer immunotherapy","volume":"77","author":"Ahmad","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib201","first-page":"5267","article-title":"Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+\/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta","volume":"62","author":"Somasundaram","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2022.e10450_bib202","first-page":"606","article-title":"Increase of regulatory T cells in the peripheral blood of cancer patients","volume":"9","author":"Wolf","year":"2003","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844022017388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844022017388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:54:06Z","timestamp":1772009646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844022017388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":202,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2405844022017388"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2022.e10450","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2022.e10450","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e10450"}}